Vanderbilt University Medical Center Nashville, Tennessee
This talk will focus on the mechanism of IL-23 in inflammatory bowel disease and subsequent development of IL12/23 and IL-23 inhibitors. The efficacy and safety data for approved and emerging IL 12/23 and IL 23 inhibitors will be discussed. Available data about which patients with inflammatory bowel disease may be best treated with IL12/23 or IL-23 inhibitors will be defined.
This session is supported by a joint educational grant from Janssen Scientific Affairs, LLC and Eli Lilly and Company
Learning Objectives:
Describe the mechanism and rationale behind the development of targeted IL-23 inhibitors
Evaluate current efficacy and safety data for approved and emerging IL-12/23 and IL-23 inhibitors for the management of IBD
Develop personalized treatment strategies for patients with IBD using data-driven decision making